A Durham biotech firm founded on technology built at Duke University has raised $175 million to fund clinical trials of its treatment that tunes gene activity within the body. Why it matters: The ...

Launched from a Duke University lab four years ago, the biotech startup Tune Therapeutics announced a major milestone ... employees split between offices in Seattle and at the downtown Durham ID ...

In less than 36 hours between the evening of Jan. 12 and the morning of Jan. 14, three local life science companies raised a ...

(Tune Photos) Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years.

The funding comes after the biotech company announced in November it was moving into the clinic with its lead drug, which is aimed at treating hepatitis B. Tune Therapeutics, which has dual ...

The Durham ID building in downtown Durham, NC holds the North Carolina office of Tune Therapeutics, a growing biotech startup moving into trials. Brian Gordon Launched from a Duke University lab ...